newsfilter
← Latest News
GlobeNewswire·

BioAge Labs to Present at Upcoming Investor Conferences

BIOA
  • BioAge Labs (NASDAQ: BIOA) will participate in the Citi Biopharma Back to School Conference (New York, Sept 9–10, 2026) with CEO Kristen Fortney, PhD, leading a fireside chat on Sept 9 & both Fortney & CFO Dov Goldstein, MD, holding one-on-one meetings.
  • The company will attend the Cantor Global Healthcare Conference (New York, Sept 9–11, 2026) where CEO Kristen Fortney, PhD, presents a fireside chat on Sept 11 & Fortney & Goldstein conduct one-on-one meetings.
  • BioAge will join the Morgan Stanley 24th Annual Global Healthcare Conference (New York, Sept 14–16, 2026) with CFO Dov Goldstein, MD, & Chief Strategy Officer BJ Sullivan, PhD, participating in a fireside chat on Sept 16 & holding one-on-one meetings.
  • Webcast replays for all events will be archived for 30 days in the investor section of the company website at https://ir.bioagelabs.com/.
  • BioAge's lead candidate BGE-102 is an oral NLRP3 inhibitor for inflammatory diseases including diabetic macular edema, having completed a Phase 1 trial with a well-tolerated profile & potential best-in-class biomarker reductions.
  • Phase 2 proof-of-concept data for BGE-102 is anticipated in the second half of 2026, with Phase 1b/2a diabetic macular edema data expected in mid-2027.
  • The company is also developing long-acting injectable & oral small molecule APJ agonists for obesity & has preclinical programs targeting metabolic aging pathways via its proprietary discovery platform.